JP2016528251A5 - - Google Patents

Download PDF

Info

Publication number
JP2016528251A5
JP2016528251A5 JP2016534804A JP2016534804A JP2016528251A5 JP 2016528251 A5 JP2016528251 A5 JP 2016528251A5 JP 2016534804 A JP2016534804 A JP 2016534804A JP 2016534804 A JP2016534804 A JP 2016534804A JP 2016528251 A5 JP2016528251 A5 JP 2016528251A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
compound
composition according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016534804A
Other languages
English (en)
Japanese (ja)
Other versions
JP6429292B2 (ja
JP2016528251A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/050783 external-priority patent/WO2015023703A1/en
Publication of JP2016528251A publication Critical patent/JP2016528251A/ja
Publication of JP2016528251A5 publication Critical patent/JP2016528251A5/ja
Application granted granted Critical
Publication of JP6429292B2 publication Critical patent/JP6429292B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016534804A 2013-08-12 2014-08-12 Ｈｅｒ２増幅性癌の処置のための方法 Expired - Fee Related JP6429292B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361865059P 2013-08-12 2013-08-12
US61/865,059 2013-08-12
US201461969003P 2014-03-21 2014-03-21
US61/969,003 2014-03-21
PCT/US2014/050783 WO2015023703A1 (en) 2013-08-12 2014-08-12 Methods for the treatment of her2 amplified cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018201232A Division JP2019031546A (ja) 2013-08-12 2018-10-25 Ｈｅｒ２増幅性癌の処置のための方法

Publications (3)

Publication Number Publication Date
JP2016528251A JP2016528251A (ja) 2016-09-15
JP2016528251A5 true JP2016528251A5 (enExample) 2017-09-21
JP6429292B2 JP6429292B2 (ja) 2018-11-28

Family

ID=52448841

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016534804A Expired - Fee Related JP6429292B2 (ja) 2013-08-12 2014-08-12 Ｈｅｒ２増幅性癌の処置のための方法
JP2018201232A Ceased JP2019031546A (ja) 2013-08-12 2018-10-25 Ｈｅｒ２増幅性癌の処置のための方法
JP2020156557A Pending JP2021008475A (ja) 2013-08-12 2020-09-17 Ｈｅｒ２増幅性癌の処置のための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018201232A Ceased JP2019031546A (ja) 2013-08-12 2018-10-25 Ｈｅｒ２増幅性癌の処置のための方法
JP2020156557A Pending JP2021008475A (ja) 2013-08-12 2020-09-17 Ｈｅｒ２増幅性癌の処置のための方法

Country Status (6)

Country Link
US (5) US9415050B2 (enExample)
EP (1) EP3033079B1 (enExample)
JP (3) JP6429292B2 (enExample)
CA (1) CA2920534A1 (enExample)
ES (1) ES2709509T3 (enExample)
WO (1) WO2015023703A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
EP2731612A4 (en) 2011-07-13 2015-04-08 Pharmacyclics Inc BRUTON TYROSINE KINASE HEMMER
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
EP3036260A4 (en) * 2013-08-20 2017-04-05 The Research Foundation for The State University of New York Bruton's tyrosine kinase as anti-cancer drug target
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
WO2016141044A1 (en) * 2015-03-04 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Erbb4 inhibitors and methods of use thereof
WO2016161347A1 (en) * 2015-04-03 2016-10-06 Pharmacyclics Llc Combinations for generating tumor-specific immunological memory
HRP20231207T1 (hr) 2015-04-06 2024-01-19 Janssen Pharmaceutica Nv Pripravak koji sadrži ibrutinib
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
AU2016303659A1 (en) * 2015-07-31 2018-02-22 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof
BR112018004175B8 (pt) * 2015-09-01 2023-10-31 Taiho Pharmaceutical Co Ltd Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto
US10668068B2 (en) * 2015-10-07 2020-06-02 The Research Foundation For The State University Of New York Treating cancer with drug combinations
CN107349426B (zh) * 2017-07-12 2018-03-23 马骥 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
TWI798334B (zh) 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
CN111053777A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 伊布替尼的药物组合物及其应用
WO2022056592A1 (en) * 2020-09-16 2022-03-24 Olivia Newton-John Cancer Research Institute Treatment and/or prevention of cancers
US20240139326A1 (en) * 2020-12-23 2024-05-02 Yeda Research And Development Co. Ltd. Methacrylamides protein binders and uses thereof

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
ATE269295T1 (de) 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
BR0014073A (pt) 1999-09-17 2002-07-16 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapêuticos
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1222187B1 (en) 1999-10-06 2004-09-22 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
AU4508601A (en) 1999-11-30 2001-06-18 Parker Hughes Institute Inhibitors of collagen-induced platelet aggregation
IL150059A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Novel heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
US20030040461A1 (en) 2000-10-23 2003-02-27 Mcatee C. Patrick Modulators of Bruton'sTyrosine Kinase and Bruton's Tyrosine Kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related diseases states
JP2004514732A (ja) 2000-12-06 2004-05-20 ファルマシア・コーポレーション 迅速に分散する医薬組成物
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
EP1463742A4 (en) 2001-06-21 2006-05-10 Ariad Pharma Inc NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
CA2810339A1 (en) 2001-08-10 2003-02-20 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
JP4391237B2 (ja) 2001-11-21 2009-12-24 サネシス ファーマシューティカルズ， インコーポレイテッド リガンド発見のための方法
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
WO2004014905A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
BRPI0418031A (pt) 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
CN1934113B (zh) 2004-01-26 2011-11-09 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的组合物
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
AU2005289728B2 (en) 2004-09-22 2011-11-24 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
WO2006036941A2 (en) 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors
KR20070063562A (ko) 2004-09-28 2007-06-19 얀센 파마슈티카 엔.브이. 치환 디피페리딘 ｃｃｒ２ 길항제
KR20070119606A (ko) 2004-11-10 2007-12-20 씨지아이 파마슈티칼스, 인크. 특정 이미다조[１,２-ａ]피라진-８-일아민, 그의 제조 방법및 용도
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
CN113952459B (zh) 2005-02-03 2025-02-11 综合医院公司 治疗吉非替尼耐药性癌症的方法
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
AU2006247757B2 (en) 2005-05-13 2009-08-27 Irm, Llc Compounds and compositions as protein kinase inhibitors
PL1893612T3 (pl) 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
WO2007058832A2 (en) 2005-11-12 2007-05-24 Boehringer Ingelheim International Gmbh Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
RU2008133161A (ru) 2006-01-13 2010-02-20 Фармасайкликс, Инк. (Us) Ингибиторы тирозин киназ и их применение
ES2420834T3 (es) 2006-01-30 2013-08-27 The Scripps Research Institute Métodos de detección de células tumorales circulantes y métodos de diagnóstico del cáncer en un sujeto mamífero
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
CA2909277A1 (en) 2006-04-04 2007-10-11 Kevan M. Shokat Kinase antagonists
RU2447891C2 (ru) 2006-04-05 2012-04-20 Новартис Аг Комбинации терапевтических средств, предназначенные для лечения рака
CA2651732C (en) 2006-05-18 2014-10-14 Mannkind Corporation Intracellular kinase inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US8987233B2 (en) 2006-11-03 2015-03-24 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
WO2008086336A1 (en) 2007-01-08 2008-07-17 Intracom Systems, Llc Multi-channel multi-access voice over ip intercommunication systems and methods
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
CA2680589A1 (en) * 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano - Bicocca Modulator compounds of the drug resistance in epithelial tumour cells
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA3001152A1 (en) 2007-03-28 2008-10-09 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN101689220A (zh) 2007-04-05 2010-03-31 奥利安实验室有限公司 用于治疗、诊断和预测医学病症发生的系统和方法
US8532276B2 (en) 2007-06-26 2013-09-10 Ingenio Llc Systems and methods to provide telephonic connections via concurrent calls
TWI475996B (zh) 2007-10-19 2015-03-11 Celgene Avilomics Res Inc 雜芳基化合物及其用途
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2205564B1 (en) 2007-10-23 2014-07-30 F. Hoffmann-La Roche AG Novel kinase inhibitors
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP3311818A3 (en) 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2010014728A1 (en) 2008-07-29 2010-02-04 Frontier Scientific Inc. Use of tetrakis (n-alkylpyridinium) -porphyrin derivatives for killing microbes or preventing growth
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
NZ620174A (en) 2009-09-16 2016-08-26 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
JP5543980B2 (ja) 2009-12-18 2014-07-09 田辺三菱製薬株式会社 新規抗血小板薬
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
BR112012033253A2 (pt) 2010-06-23 2016-11-22 Hanmi Science Co Ltd novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase
JP6068340B2 (ja) 2010-08-10 2017-01-25 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Ｂｔｋ阻害剤のベシル酸塩
US20120202611A1 (en) 2011-02-07 2012-08-09 Terry Warren Sports training device
JP5707518B2 (ja) * 2011-02-28 2015-04-30 カリトル サイエンシズ， エルエルシー 置換型キノリン化合物及び使用方法
US8722080B2 (en) 2011-03-11 2014-05-13 Gary D. Hack Treatment and prevention of dental pathology in humans and non-human animals
SI2710005T1 (sl) 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
US20130016060A1 (en) 2011-07-12 2013-01-17 Research In Motion Limited Electronic device and method of controlling a touch-sensitive display
US20130073953A1 (en) 2011-09-21 2013-03-21 Timothy Onyenobi News headline screenshot viewing system
CN110801454A (zh) 2011-10-19 2020-02-18 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的用途
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
JP5514256B2 (ja) 2012-05-18 2014-06-04 株式会社東芝 磁気記憶素子及びその製造方法
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
BR112015011171A2 (pt) 2012-11-15 2017-07-11 Pharmacyclics Inc compostos de pirrolopirimidina como inibidores da quinase
WO2014135669A1 (en) 2013-03-08 2014-09-12 Roche Diagnostics Gmbh Egfr mutation blood testing
US20160287592A1 (en) 2013-04-08 2016-10-06 Pharmacyclics Llc Ibrutinib combination therapy
EP3027192A4 (en) 2013-08-02 2017-03-22 Pharmacyclics, LLC Methods for the treatment of solid tumors
US9415050B2 (en) * 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
EP3060251A4 (en) 2013-10-25 2017-12-06 Pharmacyclics LLC Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
US20150140036A1 (en) 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof
CN106008516A (zh) 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy

Similar Documents

Publication Publication Date Title
JP2016528251A5 (enExample)
JP2016535756A5 (enExample)
RU2016122654A (ru) Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
JP7458981B2 (ja) 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
TW202038957A (zh) 抗體-藥物結合物與激酶抑制劑之組合
RU2009110102A (ru) Лечение опухолей с помощью антитела к vegf
JP2018537975A5 (enExample)
JP2015534577A5 (enExample)
JP2019501204A5 (enExample)
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
JP2019506403A5 (enExample)
AR062840A1 (es) Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2)
JP2014522843A5 (enExample)
JP2015517300A5 (enExample)
JP2015534579A5 (enExample)
RU2010142390A (ru) Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения
JP2016502504A5 (enExample)
MX2018015353A (es) Usos terapeuticos de un inhibidor de c-raf.
JP2017510661A5 (enExample)
CR10244A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
JP2020502271A5 (enExample)
TWI641385B (zh) 抗腫瘤劑及抗腫瘤效果增強劑
JP2016508973A5 (enExample)
RU2017120358A (ru) Анти-il-1-бета антитела и способы их применения